ARFORMOTEROL TARTRATE Drug Patent Profile
✉ Email this page to a colleague
When do Arformoterol Tartrate patents expire, and when can generic versions of Arformoterol Tartrate launch?
Arformoterol Tartrate is a drug marketed by Aiping Pharm Inc, Alembic, Cf Pharmtech, Cipla, Dr Reddys, Glenmark Pharms Ltd, Lupin, Mankind Pharma, Ritedose Corp, Slate Run Pharma, Sun Pharm, Teva Pharms Usa, and Wilshire Pharms Inc. and is included in thirteen NDAs.
The generic ingredient in ARFORMOTEROL TARTRATE is arformoterol tartrate. There are four drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the arformoterol tartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Arformoterol Tartrate
A generic version of ARFORMOTEROL TARTRATE was approved as arformoterol tartrate by CIPLA on June 22nd, 2021.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ARFORMOTEROL TARTRATE?
- What are the global sales for ARFORMOTEROL TARTRATE?
- What is Average Wholesale Price for ARFORMOTEROL TARTRATE?
Summary for ARFORMOTEROL TARTRATE
| US Patents: | 0 |
| Applicants: | 13 |
| NDAs: | 13 |
| Finished Product Suppliers / Packagers: | 11 |
| Raw Ingredient (Bulk) Api Vendors: | 43 |
| Clinical Trials: | 9 |
| Patent Applications: | 117 |
| Drug Prices: | Drug price information for ARFORMOTEROL TARTRATE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ARFORMOTEROL TARTRATE |
| What excipients (inactive ingredients) are in ARFORMOTEROL TARTRATE? | ARFORMOTEROL TARTRATE excipients list |
| DailyMed Link: | ARFORMOTEROL TARTRATE at DailyMed |
Recent Clinical Trials for ARFORMOTEROL TARTRATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of California, Los Angeles | Phase 4 |
| Dartmouth-Hitchcock Medical Center | Phase 4 |
| Sunovion | Phase 2 |
Pharmacology for ARFORMOTEROL TARTRATE
| Drug Class | beta2-Adrenergic Agonist |
| Mechanism of Action | Adrenergic beta2-Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for ARFORMOTEROL TARTRATE
Paragraph IV (Patent) Challenges for ARFORMOTEROL TARTRATE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| BROVANA | Inhalation Solution | arformoterol tartrate | Eq. 0.015 mg base/ 2 mL | 021912 | 1 | 2009-10-01 |
US Patents and Regulatory Information for ARFORMOTEROL TARTRATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aiping Pharm Inc | ARFORMOTEROL TARTRATE | arformoterol tartrate | SOLUTION;INHALATION | 214901-001 | Apr 2, 2024 | AN | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Lupin | ARFORMOTEROL TARTRATE | arformoterol tartrate | SOLUTION;INHALATION | 213068-001 | Feb 7, 2022 | AN | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Cipla | ARFORMOTEROL TARTRATE | arformoterol tartrate | SOLUTION;INHALATION | 207306-001 | Jun 22, 2021 | AN | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Teva Pharms Usa | ARFORMOTEROL TARTRATE | arformoterol tartrate | SOLUTION;INHALATION | 200293-001 | Nov 9, 2021 | AN | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Mankind Pharma | ARFORMOTEROL TARTRATE | arformoterol tartrate | SOLUTION;INHALATION | 216128-001 | Nov 15, 2022 | AN | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Alembic | ARFORMOTEROL TARTRATE | arformoterol tartrate | SOLUTION;INHALATION | 214779-001 | May 10, 2022 | AN | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Cf Pharmtech | ARFORMOTEROL TARTRATE | arformoterol tartrate | SOLUTION;INHALATION | 216303-001 | May 17, 2024 | AN | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
